Location of Repository

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease

By Vlad Ratziu, Julien Massard, Frederic Charlotte, Djamila Messous, Françoise Imbert-Bismut, Luninita Bonyhay, Mohamed Tahiri, Mona Munteanu, Dominique Thabut, Jean François Cadranel, Brigitte Le Bail, Victor de Ledinghen and Thierry Poynard
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:1386692
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Preview

    Citations

    1. (2002). AGA technical review on nonalcoholic fatty liver disease. Gastroenterology
    2. (1998). AJ: Non-alcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol
    3. (1982). Alpha 2-macroglobulin and proliferative retinopathy in type 1 diabetes. Horm Metab Res
    4. (2000). Appropriateness of liver biopsy.
    5. (2003). Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology
    6. (2005). Biomarkers as a first-line estimate of injury in chronic liver diseases: time for a moratorium on liver biopsy? Gastroenterology
    7. (2005). Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol
    8. (1990). BJ: A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology
    9. (1988). Clarke-Pearson DL: Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics
    10. (2004). Contreras R: Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med
    11. (2005). De Ledinghen V: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology
    12. (2002). Degos F: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat
    13. (2000). Degos F: Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology
    14. (2004). Deugnier Y: Prediction of liver fibrosis in patients with features of the metabolic syndrome regardless of alcohol consumption. Hepatology
    15. (1989). Diehl AM: Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med
    16. (2002). DR: Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in culture.
    17. (2002). Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology
    18. (2005). FibroTestFibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn
    19. (2005). for the LIDO Study Group: Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology
    20. (2004). Hainque B: Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol
    21. (1991). JD: Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol
    22. (2001). JM: alpha 2-Macroglobulin: a new component in the insulin-like growth factor/insulin-like growth factor binding protein-1 axis.
    23. (2005). Kinjo F, Saito A: Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease.
    24. (1999). Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology
    25. (1999). Lindor KD: The ratio of aspartate aminotransferase to alanine aminotransferase: potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease.
    26. (2002). MJ: The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology
    27. (2004). Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol
    28. (2002). Nonalcoholic fatty liver disease.
    29. (2006). O: Independent prospective multicenter validation of biochemical markers (Fibrotest-Actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C. Am J Gastro
    30. (2004). on behalf of the European Liver Fibrosis Group: Serum Markers Detect the Presence of Liver Fibrosis: A Cohort Study. Gastroenterology
    31. (2001). PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology
    32. (1973). PM: The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism.
    33. (2002). Poynard T: A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol
    34. (2001). Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet
    35. (2002). Poynard T: Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C.
    36. (2004). Poynard T: Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med
    37. (2004). Poynard T: Intraindividual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest). Comp Hepatol
    38. (2000). Poynard T: Liver fibrosis in overweight patients. Gastroenterology
    39. (2003). Poynard T: Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol
    40. (2002). Poynard T: Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology
    41. (2004). Ratziu V: Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. Clin Chem
    42. (1963). Role of alpha-2-macroglobulin of human serum in the fixation in vitro of iodine-131 labeled bovine insulin. Helv Med Acta
    43. (2003). Sanyal AJ: Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology
    44. (2003). Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. Aids
    45. (2003). SH: Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatology
    46. (2004). Silent non-alcoholic fatty liver disease-a clinical-histological study.
    47. (2002). Statistical Methods in Diagnostic Medicine Edited by:
    48. (1991). SV: Mechanism of insulin incorporation into alpha 2-macroglobulin: implications for the study of peptide and growth factor binding. Biochemistry
    49. (2004). Tiribelli C: The epidemiology of fatty liver.
    50. (2005). Trepo C: Longitudinal assessment of histology surrogate markers (Fibrotest-Actitest) during lamivudine therapy in patients with chronic hepatitis B infection.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.